FDA Approves First-of-Its-Kind Device for Locally Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved Optune Pax®, a first-of-its-kind portable device that delivers Tumor Treating Fields (TTFields) for the treatment of adult patients with locally advanced pancreatic cancer. This approval, granted on February 12, 2026, marks the first new treatment option for this challenging cancer in nearly 30 years .

How Optune Pax Works

Optune Pax is a non-invasive device that delivers alternating electrical fields, known as TTFields, to the abdomen. These fields disrupt the rapid cell division characteristic of cancer cells, although minimizing damage to healthy tissue . The device is designed to be worn with the generator carried in a specially designed bag, allowing patients to receive continuous treatment while maintaining their daily activities .

Clinical Trial Results: PANOVA-3

The approval of Optune Pax is based on the results of the Phase 3 PANOVA-3 clinical trial. The trial, involving 571 participants, demonstrated a statistically significant improvement in overall survival for patients treated with Optune Pax in combination with gemcitabine and nab-paclitaxel . Specifically, patients receiving TTFields alongside chemotherapy lived an average of 16.2 months, compared to 14.2 months for those receiving chemotherapy alone .

Beyond overall survival, the trial also showed that patients treated with Optune Pax experienced a significant extension in time to pain progression – an additional six months – and reported improvements in several quality-of-life measures, including digestive problems and fatigue .

Who Can Benefit from Optune Pax?

This treatment is approved for patients with unresectable, locally advanced pancreatic adenocarcinoma. This means the cancer has not spread widely but is advanced enough that surgical removal is not currently feasible .

Side Effects

The most common side effect reported with Optune Pax is mild to moderate skin irritation under the device arrays. Patients may also experience mild warming or tingling sensations in the treated area .

What’s Next for Patients?

Patients with locally advanced pancreatic cancer should discuss this new treatment option with their healthcare team. The Pancreatic Cancer Action Network (PanCAN) Patient Services offers resources, including personalized clinical trial searches and a list of specialists, to help patients navigate their treatment options .

Insurance Coverage

FDA approval typically leads to coverage by Medicare and Medicaid, and most private insurance plans will likely follow suit. However, coverage can vary depending on the specific plan. PanCAN Patient Services can provide information on financial assistance programs for patients facing cost-related barriers to care .